Beth Israel Deaconess Medical Center (BIDMC), a major teaching affiliate of
Harvard Medical School, offers a
training program in hematology and medical oncology which fully integrates these subspecialties into a single service.
The aim of the program is to produce scholars who will devote their careers, in different proportions, to clinical care, teaching, and clinical or basic research. Every effort is made to tailor the program to the specific needs of trainees, in order to help them achieve their early career goals, whether those are to pursue laboratory research or a clinical career. The program directors expect that all graduates of the training program will become first-class clinicians and teachers and that all will have substantial exposure to investigative work in either a basic or a clinical field.
In recognition of the program's success in producing physician-scientists, the NIH has provided training grant support to the program for over 30 years. The program directors are equally proud of graduates who have entered careers more concerned with clinical care and clinical research. The program in hematology and oncology at BIDMC is expanding in both clinical and scientific breath. The merger between the Beth Israel and New England Deaconess Hospitals in 1996 precipitated dramatic growth in academic and clinical programs. The number of patients seen has grown progressively, and there is a vast array of patients with common and more exoteric clinical disorders. Clinical and basic science investigational programs are expanding with the recruitment of new faculty members who have diverse, exciting research interests. Clinical investigations include programs in bone marrow transplantation, biologic modifers, genitourinary malignancies, breast cancer, lung cancer, head and neck cancer, gastrointestinal malignancies, AIDS-related malignancies, and experimental therapeutics.
Basic research investigations include programs in signal transduction and growth regulation in normal and neoplastic cells; the role of transcription factors in hematopoiesis and the molecular analysis of hematopoietic stem cell differentiation; the biology of prostate cancer and the molecular basis of hormone-independent prostate cancer growth; the biology of AIDS-related malignancies; T-cell receptor biology as applied to gene therapy; hemostasis, thrombosis, and vascular biology; molecular retrovirology and HIV-gene therapy; the molecular biology and biochemistry of erythropoietin; and the immunobiology of cytokines.